Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor|Breast Cancer
Interventions: DRUG: F16IL2 in combination with doxorubicin
Sponsor: Philogen S.p.A.